Bone Cancer

BONE CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes

One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse

More than one-third of tumors sequenced carried a high mutation burden.
Adult Participation in Cancer Trials Higher Than Previously Thought

Enrollment rates varied widely by study type and institution.
First-Line Immunotherapy Continues to Best Chemo in Malignant Pleural Mesothelioma

Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
How to Prevent a Cyberattack from Derailing Cancer Care

Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.

BONE CANCER NEWS

FDA_drug approval

Crysvita Approved for Treatment of Tumor-Induced Osteomalacia

June 23, 2020

Strontium89 Now Available for Relief of Metastatic Bone Pain

February 14, 2020

A recent article is only the latest in a series of studies drawing attention to the importance of di

FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma

May 2, 2018

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma

CTA Treatment Regimen Chart for Bone Cancer Updated

August 9, 2016

Pacritinib induced significant and sustained spleen volume reduction and symptom control in patients

Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma

July 12, 2016

Next post in Bone Cancer

Bone Cancer Treatment Regimens